<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758470</url>
  </required_header>
  <id_info>
    <org_study_id>H16-00896</org_study_id>
    <nct_id>NCT02758470</nct_id>
  </id_info>
  <brief_title>Muscle Fatigue and Carbonic Anhydrase Inhibitors</brief_title>
  <official_title>The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this research is to assess the effects of acetazolamide and methazolamide on
      respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for
      the respiratory and plantar flexor muscles and the difference in pressure/torque produced by
      supramaximal nerve stimulation used to assess muscle fatigue between conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in trans-diaphragmatic pressure generation to supramaximal phrenic nerve stimulation following inspiratory threshold loading.</measure>
    <time_frame>Baseline, 1, 5, 10, 20, and 30 minutes following the loading protocol for each arm of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plantar flexor muscle group torque generation to supramaximal tibial nerve stimulation following an isometric loading protocol</measure>
    <time_frame>Baseline, 1, 5, 10, 20, and 30 minutes following the loading protocol for each arm of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal inspiratory pressure maneuvers</measure>
    <time_frame>Baseline and immediately following loading protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Voluntary Contraction of the Plantar Flexor Muscle Group</measure>
    <time_frame>Baseline and immediately following the loading protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraction time and half-relaxation time</measure>
    <time_frame>Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Esophageal and Gastric Pressure</measure>
    <time_frame>Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Beat-by-beat blood pressure</measure>
    <time_frame>Baseline, 1, 5, 10, 20, and 30 minutes post loading protocol</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hypoxia</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>250 mg, taken orally three times per day</description>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methazolamide</intervention_name>
    <description>100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.</description>
    <arm_group_label>Methazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be taken three times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-40 years.

          -  Regularly physically active

          -  Male

        Exclusion Criteria:

          -  current or ex-smokers

          -  pulmonary function &lt;80% of predicted

          -  esophageal tumour or ulcer

          -  have had recent (&lt;6 months) musculoskeletal injury or any surgery to the lower leg

          -  have contraindications to carbonic anhydrase inhibitors (eg. severe or absolute
             glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency,
             sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis)

          -  are obese (BMI &gt;30 Kg/m2)

          -  taking diuretics, blood thinners, or anti-platelet drugs.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glen E Foster, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1V 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Dominelli PB, McNeil CJ, Vermeulen TD, Stuckless TJR, Brown CV, Dominelli GS, Swenson ER, Teppema LJ, Foster GE. Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial. J Appl Physiol (1985). 2018 Sep 1;125(3):770-779. doi: 10.1152/japplphysiol.00256.2018. Epub 2018 May 24.</citation>
    <PMID>29792554</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Glen Foster</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Muscle Fatigue</keyword>
  <keyword>Acetazolamide</keyword>
  <keyword>Methazolamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Methazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

